Alcon’s AutonoMe IOL Injector Gains CE Mark Approval

October 6, 2017: By Joan McKenna
Alcon AutotonoMe IOL Delivery System

Alcon AutotonoMe IOL Delivery System

Alcon’s AutonoMe preloaded intraocular lens delivery system for its Clareon IOL has gained CE mark approval, parent Novartis announced Oct. 6.

The new device will be introduced with the Clareon IOL at the 2017 meeting of the European Society of Cataract and Refractive Surgeons in Lisbon, Portugal.

“Throughout Alcon’s history, we have worked with doctors to enhance and transform the way cataract surgery is performed,” said Mike Ball, chief executive officer of Alcon, in Fort Worth Texas. “Clareon AutonoMe builds upon the comprehensive legacy of AcrySof by offering cataract surgeons easy, intuitive control of IOL delivery with the newest optic material.”

Features of the AutonoMe include an automated CO2-powered delivery mechanism and an intuitive, ergonomic design to allow precise and simplified single-handed control of IOL placement during cataract surgery, Switzerland-based Novartis said.

The Clareon hydrophobic acrylic IOL, made of a new biomaterial designed to provide sharp vision and optical clarity, received CE mark approval in May.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Imprimis Offers Compounded Alternative to Restasis for Dry Eye

US District Court Invalidates Four Restasis Patents

BioTime Prices $25 Million Public Offering of Common Stock

Gemini Completes $42.5 Million Series A Financing for Dry AMD Treatment

BIOPHYTIS Raises €10.4 Million to Develop Anti-Aging Drugs, One for Dry AMD

Amydis Receives $530 Thousand NIH Award to Advance Ophthalmic Diagnostic Probes

Realm Announces Completion of $26 million Private Placement

Sight Sciences Secures $10 Million in Oversubscribed Series C Financing

Aerpio Names Stephen Hoffman CEO; Founder Joseph Gardner Remains President

FDA Advisory Panel Recommends Aerie’s Rhopressa for Glaucoma Patients

FDA Panel Unanimously Backs Spark’s Luxturna as Retinal Gene Therapy

PanOptica Secures $11 Million to Advance Topical Anti-VEGF Eye Drop for Neovascular AMD

Nicox and pSivida to Collaborate to Develop a Sustained Release Drug to Lower IOP

Azura Nets $16 Million in Series B Funding for Dry Eye Treatment

Alcon’s AcrySof Intraocular Lens Reaches 100 Million Implants

Notal Vision’s ForeseeHome Reaches Milestone of 3 Million Tests

FDA to Review Spark’s Retinal Gene Therapy Candidate Oct. 12

Alcon’s AutonoMe IOL Injector Gains CE Mark Approval

Shire Sues Allergan, Claiming Bundling Tactics Block Restasis Competitors

Allergan Decries ‘Unfair’ Patent Challenge Process as US House Launches Probe of Tribe Deal

Coming soon

2017 Refractive Surgery Report: A Global Market Analysis for 2016 to 2022